Table II:
TCD50-and RBE-values for three tumor sublines of the R3327 prostate carcinoma measured in this and a previous study [11].
| Endpoint | TCD50 ± SE (90% CI) [Gy] | RBE ± SE (90% CI) | |
|---|---|---|---|
| Photons* | 12C-ions* | ||
| H-Tumor (this study) | |||
| LC (300 d) | 338.2 ± 1.8 (34.0 – 41.1) § | 23.6 ± 1.1 (21.5 – 25.8) | 1.62 ± 0.11 (1.45 – 1.81) |
| Histo† | 48.3 ± 2.8 (43.6 – 54.6) | 26.8 ± 1.0 (24.9 – 28.8) | 1.80 ± 0.13 (1.60 – 2.02) |
| HI-Tumor (this study) | |||
| LC (300 d) | 62.4 ± 3.2 (56.6 – 69.8) § | 30.0 ± 1.1 (27.5 – 32.6) $ | 2.08 ± 0.13 (1.87 – 2.30) & |
| LC (320 d)‡ | 63.9 ± 3.9 (57.5 – 74.7) | 31.6 ± 1.6 (28.7 – 35.5) | 2.03 ± 0.16 (1.78 – 2.30) |
| AT1-Tumor [11] | |||
| LC (300 d) | 75.7 ± 1.6 (69.9 – 78.6) § | 32.9 ± 0.9 (30.8 – 34.9) $ | 2.30 ± 0.08 (2.17 – 2.44) & |
Uncertainties are given as single standard errors and 90%-confidence intervals. Endpoints for this dose-response study were “local tumor control (LC) within 300 d or 320 d” or “histological tumor control” (Histo).
All differences in TCD50 between photons and 12C-ions for the same tumor and endpoint are highly significant (p<0.0005).
All differences in TCD50 at LC (300 d) between tumor sublines are highly significant (p<0.0005).
Differences in TCD50 at LC (300 d) relative to the H-tumor are highly significant (p<0.0005), but only significant (p<0.05) for HI vs AT1.
Differences in RBE at LC (300 d) relative to the H-tumor are highly significant (p<0.0005) for the AT1- and significant (p<0.05) for the HI-tumor.
Difference relative to LC (300 d) is significant (p<0.05) for TCD50-values, but not for the RBE.
No significant difference for TCD50 and RBE relative to LC (300 d)